Related Experiment Video
Updated: Jan 13, 2026
Transplantation of Pulmonary Valve Using a Mouse Model of Heterotopic Heart Transplantation
Published on: July 23, 2014
Pediatric heart transplant survival in single ventricle disease
1Division of Pediatric Cardiology, Morgan Stanely Children's Hospital, Columbia University Irving Medical Center, New York, NY.
Insights
Pediatric heart transplant outcomes are improving, but patients with congenital heart disease (CHD) still face higher risks. Further research into co-morbidities is needed to enhance survival and quality of life.
Area of Science:
- Cardiology
- Pediatric Surgery
- Immunology
Background:
- Pediatric heart transplantation outcomes have improved since 1967.
- Congenital heart disease (CHD) patients experience worse outcomes, including waitlist mortality and post-transplant survival.
- Single ventricle disease (SVD) poses a high risk for rejection and severe hemodynamic compromise (RSHC).
Purpose of the Study:
- To review the current outcomes and challenges in pediatric heart transplantation.
- To highlight persistent issues such as cardiac allograft vasculopathy (CAV) and post-transplant lymphoproliferative disease (PTLD).
- To emphasize the need for continued advancements to improve long-term survival and quality of life.
Main Methods:
- Literature review of pediatric heart transplantation outcomes.
- Analysis of patient data focusing on specific conditions like CHD and SVD.
- Examination of trends in complications such as CAV and PTLD.
Main Results:
- Patients with CHD, particularly SVD, face significantly higher risks for adverse outcomes.
- Limited progress has been made in preventing or treating cardiac allograft vasculopathy (CAV) and post-transplant lymphoproliferative disease (PTLD).
- Survival rates following diagnosis of CAV and PTLD remain poor across all pediatric heart transplant recipients.
Conclusions:
- Despite overall improvements, significant challenges persist in pediatric heart transplantation, especially for CHD patients.
- Further research and advancements in immunosuppression, mechanical support, and surgical techniques are crucial.
- Improving understanding of co-morbidities is essential to enhance survival and quality of life for pediatric heart transplant recipients.
Abstract:
Outcomes in pediatric heart transplantation have steadily improved since the first pediatric heart transplant was performed by Dr. Kantrowitz and his team in 1967; however, there is still progress to be made. Patients with congenital heart diseases (CHD) consistently have worse waitlist mortality, post-transplant survival, infection rates, and post-transplant lymphoproliferative disease (PTLD) risk, with single ventricle disease (SVD) patients being at particularly high risk for rejection and rejection with severe hemodynamic compromise (RSHC). Furthermore, there has been little improvement in the development of cardiac allograft vasculopathy (CAV) and PTLD over the decades, and survival following diagnosis continues to remain poor for all patients regardless of diagnosis. Hopefully, as new advances in immunosuppression, mechanical support, and surgical techniques emerge, we will continue to develop a deeper understanding of the co-morbidities associated with pediatric heart transplant to further improve the survival and quality of life of pediatric heart transplant recipients.
